tetano
Editor, Senior Moderator
Res Pract Thromb Haemost
. 2022 Jun 17;6(4):e12743.
doi: 10.1002/rth2.12743. eCollection 2022 May.
No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease
Jérémie Botton[SUP] 1 [/SUP], Laura Semenzato[SUP] 1 [/SUP], Julie Dupouy[SUP] 2 [/SUP], Rosemary Dray-Spira[SUP] 1 [/SUP], Alain Weill[SUP] 1 [/SUP], Olivier Saint-Lary[SUP] 3 [/SUP], Mahmoud Zureik[SUP] 1 3 [/SUP]
Affiliations
Abstract
Background: Aspirin at low doses has been reported to be a potential drug candidate to treat or prevent severe coronavirus disease 2019 (COVID-19).
Objectives: We aimed to explore whether low-dose aspirin used for primary cardiovascular prevention was associated with a lower risk of severe COVID-19.
Method: A large cohort of patients without known cardiovascular comorbidities was constructed from the entire French population registered in national health care databases. In total, 31.1 million patients aged ≥40 years, including 1.5 million reimbursed for low-dose aspirin at least at three time points during the 6 months before the epidemic, were followed until hospitalization with a COVID-19 diagnosis or intubation/death for hospitalized patients.
Results: Cox models adjusted for age and sex showed a positive association between low-dose aspirin and the risk of hospitalization (hazard ratio
, 1.33; 95% confidence interval (CI), 1.29-1.37]) or death/intubation (HR, 1.40 [95% CI, 1.33-1.47]). In fully adjusted models, associations were close to null (HR, 1.03 [95% CI, 1.00-1.06] and 1.04 [95% CI, 0.98-1.10], respectively).
Conclusion: There was no evidence for an effect of low-dose aspirin for primary cardiovascular prevention in reducing severe COVID-19.
Keywords: COVID‐19; aspirin; pharmacoepidemiology; primary cardiovascular prevention; public health.
. 2022 Jun 17;6(4):e12743.
doi: 10.1002/rth2.12743. eCollection 2022 May.
No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease
Jérémie Botton[SUP] 1 [/SUP], Laura Semenzato[SUP] 1 [/SUP], Julie Dupouy[SUP] 2 [/SUP], Rosemary Dray-Spira[SUP] 1 [/SUP], Alain Weill[SUP] 1 [/SUP], Olivier Saint-Lary[SUP] 3 [/SUP], Mahmoud Zureik[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35755854
- PMCID: PMC9204394
- DOI: 10.1002/rth2.12743
Abstract
Background: Aspirin at low doses has been reported to be a potential drug candidate to treat or prevent severe coronavirus disease 2019 (COVID-19).
Objectives: We aimed to explore whether low-dose aspirin used for primary cardiovascular prevention was associated with a lower risk of severe COVID-19.
Method: A large cohort of patients without known cardiovascular comorbidities was constructed from the entire French population registered in national health care databases. In total, 31.1 million patients aged ≥40 years, including 1.5 million reimbursed for low-dose aspirin at least at three time points during the 6 months before the epidemic, were followed until hospitalization with a COVID-19 diagnosis or intubation/death for hospitalized patients.
Results: Cox models adjusted for age and sex showed a positive association between low-dose aspirin and the risk of hospitalization (hazard ratio
, 1.33; 95% confidence interval (CI), 1.29-1.37]) or death/intubation (HR, 1.40 [95% CI, 1.33-1.47]). In fully adjusted models, associations were close to null (HR, 1.03 [95% CI, 1.00-1.06] and 1.04 [95% CI, 0.98-1.10], respectively).
Conclusion: There was no evidence for an effect of low-dose aspirin for primary cardiovascular prevention in reducing severe COVID-19.
Keywords: COVID‐19; aspirin; pharmacoepidemiology; primary cardiovascular prevention; public health.